Trump Media and Technology Group Corp vs Erasca Inc. Common Stock — how do they compare? Trump Media and Technology Group Corp trades at $8.12 (market cap $2.28B), while Erasca Inc. Common Stock trades at $15.97 (market cap $5.40B). The key difference: Erasca Inc. Common Stock is far larger — about 2.4× Trump Media and Technology Group Corp's market cap, and Erasca Inc. Common Stock is trading nearer its 52-week high, Trump Media and Technology Group Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Trump Media and Technology Group Corp for 17 Days and Erasca Inc. Common Stock for 0 Days on average.
| DJT | ERAS | |
|---|---|---|
Market Cap | $2.28B | $5.40B |
Volume | 3,148,379 | 9,533,185 |
Sector | Media | Health |
52-Week High | $17.07 | $22.47 |
52-Week Low | $7.06 | $2.20 |
Typical Hold Time | 17 Days | 0 Days |
Enterprise Value | $2.35B | $5.18B |
Signals from Pluang's Aura AI — not financial advice
DJT trades at $8.11, down 1.34% with bearish technical signals. The company reported $3.68M revenue in 2025 but a net loss of $712M, with negative margins and cash flow challenges. Recent news highlights a proposed merger with TAE Technologies and ongoing volatility linked to political developments and strategic shifts.
Outlook remains high-risk due to persistent losses and speculative sentiment. The merger with TAE offers potential diversification into fusion energy, but profitability concerns and insider selling weigh on investor confidence. Key risks include execution hurdles and dependence on political narratives.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Trump Media & Technology Group is a media firm rooted in social media and digital streaming. Its flagship product, Truth Social, provides a platform focused on free speech and open conversation.
Read more on DJT →Erasca is a biotechnology company developing precision medicines for cancer. Its programs target genetic drivers of tumor growth.
Read more on ERAS →